WallStreetZenWallStreetZen

NASDAQ: XFOR
X4 Pharmaceuticals Inc Stock

$1.39-0.02 (-1.42%)
Updated Mar 28, 2024
XFOR Price
$1.39
Fair Value Price
$0.23
Market Cap
$233.43M
52 Week Low
$0.57
52 Week High
$2.58
P/E
-2.44x
P/B
4.57x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$101.17M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.88
Operating Cash Flow
-$97M
Beta
1.09
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A

XFOR Overview

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how XFOR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

XFOR ($1.39) is overvalued by 500.12% relative to our estimate of its Fair Value price of $0.23 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
XFOR ($1.39) is not significantly undervalued (500.12%) relative to our estimate of its Fair Value price of $0.23 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
XFOR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more XFOR due diligence checks available for Premium users.

Be the first to know about important XFOR news, forecast changes, insider trades & much more!

XFOR News

Valuation

XFOR fair value

Fair Value of XFOR stock based on Discounted Cash Flow (DCF)
Price
$1.39
Fair Value
$0.23
Overvalued by
500.12%
XFOR ($1.39) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
XFOR ($1.39) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
XFOR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

XFOR price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-2.44x
Industry
14.26x
Market
44.51x

XFOR price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
4.57x
Industry
6.21x
XFOR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

XFOR's financial health

Profit margin

Revenue
$0.0
Net Income
-$19.1M
Profit Margin
0%
XFOR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$147.3M
Liabilities
$96.2M
Debt to equity
1.88
XFOR's short-term assets ($122.08M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
XFOR's short-term assets ($122.08M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
XFOR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
XFOR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$27.7M
Investing
-$4.8M
Financing
$97.0k
XFOR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

XFOR vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
XFOR$233.43M-1.42%-2.44x4.57x
CRMD$233.12M+1.92%-4.66x3.32x
FGEN$232.11M-8.91%-0.80x-1.14x
IPHA$231.89M+21.01%-29.39x4.11x
VNDA$236.48M+5.66%102.75x0.43x

X4 Pharmaceuticals Stock FAQ

What is X4 Pharmaceuticals's quote symbol?

(NASDAQ: XFOR) X4 Pharmaceuticals trades on the NASDAQ under the ticker symbol XFOR. X4 Pharmaceuticals stock quotes can also be displayed as NASDAQ: XFOR.

If you're new to stock investing, here's how to buy X4 Pharmaceuticals stock.

What is the 52 week high and low for X4 Pharmaceuticals (NASDAQ: XFOR)?

(NASDAQ: XFOR) X4 Pharmaceuticals's 52-week high was $2.58, and its 52-week low was $0.57. It is currently -46.02% from its 52-week high and 143.01% from its 52-week low.

How much is X4 Pharmaceuticals stock worth today?

(NASDAQ: XFOR) X4 Pharmaceuticals currently has 167,937,781 outstanding shares. With X4 Pharmaceuticals stock trading at $1.39 per share, the total value of X4 Pharmaceuticals stock (market capitalization) is $233.43M.

X4 Pharmaceuticals stock was originally listed at a price of $84.18 in Nov 16, 2017. If you had invested in X4 Pharmaceuticals stock at $84.18, your return over the last 6 years would have been -98.35%, for an annualized return of -49.54% (not including any dividends or dividend reinvestments).

How much is X4 Pharmaceuticals's stock price per share?

(NASDAQ: XFOR) X4 Pharmaceuticals stock price per share is $1.39 today (as of Mar 28, 2024).

What is X4 Pharmaceuticals's Market Cap?

(NASDAQ: XFOR) X4 Pharmaceuticals's market cap is $233.43M, as of Mar 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

X4 Pharmaceuticals's market cap is calculated by multiplying XFOR's current stock price of $1.39 by XFOR's total outstanding shares of 167,937,781.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.